Horizon and Mallinckrodt to co-promote Duexis

Monday, June 18, 2012 09:54 AM

Mallinckrodt, the pharmaceuticals business of Covidien, has entered into a co-promotion agreement with Horizon Pharma of Deerfield, Ill., to promote the latter’s proprietary drug Duexis, a single-tablet combination of ibuprofen and the histamine H2-receptor antagonist famotidine for symptom relief of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.

Mallinckrodt’s U.S. sales force will sell Duexis through December 31, 2014. Horizon and Mallinckrodt have agreed upon physician promotion targets and Mallinckrodt will be compensated for each prescription generated from these targets. The Mallinckrodt sales force is expected to begin promoting Duexis to physicians in August 2012. Horizon will continue to record all revenues and remain responsible for Duexis manufacturing, supply and regulatory activities.

"This agreement represents a key component of our growing pharmaceuticals business as Mallinckrodt prepares to spin off from Covidien next year,” said Mark Trudeau, president of pharmaceuticals, Mallinckrodt. “We are leaders in pain management, and adding Duexis to our portfolio will further advance our efforts to help patients manage the often-debilitating impact of pain.”

Mallinckrodt is the largest U.S. supplier of opioid pain medications and among the top 10 generic pharmaceuticals manufacturers in the U.S., based on prescriptions. Its branded portfolio includes Exalgo (hydromorphone HCl) extended-release tablets and Pennsaid (diclofenac sodium topical solution) 1.5% w/w. Mallinckrodt is also one of the world’s leading producers of bulk acetaminophen.

“The addition of Mallinckrodt’s experienced sales force will expand our reach and frequency into the osteoarthritis and rheumatology markets,” said Timothy P. Walbert, chairman, president and CEO, Horizon Pharma.




Browse by:


December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs